Investigational Drug Information for Taselisib
What is the drug development status for Taselisib?
Taselisib is an investigational drug.
There have been 10 clinical trials for Taselisib.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 9th 2015.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Genentech, Inc., and Southwest Oncology Group.
Summary for Taselisib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,627 |
| WIPO Patent Applications | 642 |
| Japanese Patent Applications | 75 |
| Clinical Trial Progress | Phase 3 (2015-04-09) |
| Vendors | 65 |
Recent Clinical Trials for Taselisib
| Title | Sponsor | Phase |
|---|---|---|
| Trial of Taselisib in Overgrowth | Centre Hospitalier Universitaire Dijon | Phase 1/Phase 2 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | National Cancer Institute (NCI) | Phase 2 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Taselisib
Top disease conditions for Taselisib
Top clinical trial sponsors for Taselisib
US Patents for Taselisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Taselisib Development Update, Patent Status, FDA Outlook, and Market Projection
Taselisib, also known as GDC-0032, is a Roche/Genentech investigational oral PI3K inhibitor that was developed primarily for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer. Roche discontinued the program after the Phase 3 SANDPIPER trial showed a modest progression-free survival benefit but substantial toxicity, no demonstrated overall-survival benefit, and limited commercial differentiation from approved PI3K-pathway drugs.[1][2]
Taselisib has no FDA approval, no Orange Book listing, no marketed product, and no credible standalone revenue outlook. Its current commercial value is effectively zero unless Roche or another company revives development in a new biomarker-selected setting.
What is the current development status of taselisib?
Taselisib development has been discontinued.
Roche evaluated taselisib as an oral, selective inhibitor of PI3K alpha and PI3K delta, with additional activity against PI3K beta and PI3K gamma at higher concentrations. The candidate was designed to inhibit signaling driven by activating PIK3CA mutations, which occur frequently in breast cancer and other solid tumors.
The principal development program was:
| Development program | Disease setting | Regimen | Outcome |
|---|---|---|---|
| SANDPIPER | PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer | Taselisib plus fulvestrant versus placebo plus fulvestrant | Positive PFS result, unfavorable benefit-risk profile |
| Phase 1/2 studies | Advanced solid tumors | Taselisib monotherapy or combination therapy | Antitumor activity, dose-limiting toxicity |
| Other exploratory studies | Breast, colorectal, lung and other solid tumors | Various combinations | No registrational path established |
In 2018, Roche announced that it would not pursue a regulatory filing for taselisib in breast cancer. The company subsequently terminated or discontinued major clinical development activities. The SANDPIPER findings were published in 2018 and confirmed that the efficacy gain was insufficient to justify the toxicity burden.[1]
What did the Phase 3 SANDPIPER trial show?
SANDPIPER enrolled patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer whose disease had progressed during or after aromatase-inhibitor therapy. Patients received fulvestrant with either taselisib or placebo.
The key results were:
| Endpoint | Taselisib plus fulvestrant | Placebo plus fulvestrant |
|---|---|---|
| Median progression-free survival | 7.4 months | 5.4 months |
| Progression-free survival hazard ratio | 0.70 | Reference |
| Grade 3 or 4 adverse events | Approximately 55.8% | Approximately 21.7% |
| Treatment discontinuation due to adverse events | Approximately 16.8% | Approximately 2.3% |
The PFS improvement was statistically significant, but the absolute benefit was about two months. Toxicities included hyperglycemia, diarrhea, colitis, rash, stomatitis and pneumonitis. The trial did not establish a clinically compelling overall-survival advantage.[1][2]
The SANDPIPER result demonstrated that PIK3CA mutation selection alone did not produce a sufficient therapeutic index for taselisib. This became a major competitive disadvantage as less toxic or more selective PI3K-pathway agents entered development.
Why was taselisib discontinued?
Taselisib was discontinued because its efficacy did not offset its safety profile.
The primary commercial and regulatory problems were:
- The PFS benefit was modest.
- Grade 3 and 4 toxicity was substantially higher than with fulvestrant alone.
- Hyperglycemia, diarrhea and colitis created treatment-management burdens.
- The program did not establish an overall-survival benefit.
- Competing agents offered more focused development strategies.
- Roche had no approved indication to support a commercial launch or label expansion.
The regulatory environment also changed after the FDA approved alpelisib, a PI3K alpha inhibitor, for PIK3CA-mutated HR-positive, HER2-negative advanced or metastatic breast cancer in 2019. Alpelisib was developed with a more direct molecular selectivity strategy and became the established commercial benchmark for this segment.[3]
What is the FDA regulatory status of taselisib?
Taselisib is not FDA approved.
There is no public evidence that Roche submitted a New Drug Application for taselisib. The drug therefore has:
| FDA status item | Taselisib status |
|---|---|
| FDA approval | None |
| Approved indication | None |
| NDA approval | None publicly reported |
| Breakthrough Therapy approval | None |
| Priority Review approval | None |
| FDA label | None |
| REMS program | None |
| Orange Book listing | None |
| Authorized generic | None |
Because taselisib was never approved, it does not have FDA-granted drug exclusivity associated with a marketed product. It also does not have a listed therapeutic-equivalence framework for generic substitution.
What patents protect taselisib?
Taselisib was protected by Roche and Genentech patent families covering PI3K-inhibitor chemical matter, pharmaceutical compositions and therapeutic uses. The patent estate was commercially relevant during clinical development but has limited present value because the underlying clinical program was terminated.
Publicly associated U.S. patent records include composition-of-matter and PI3K-inhibitor patent families assigned to Genentech or related Roche entities. A representative family is associated with U.S. Patent No. 8,598,219, directed to PI3K-inhibitor compounds. The relevant patent families were filed many years before the SANDPIPER readout and generally have statutory terms running into the mid-2020s, subject to patent-term adjustment, terminal disclaimers, continuations and jurisdiction-specific expiry rules.[4]
The commercial patent position should be separated from regulatory exclusivity:
| Protection category | Taselisib position |
|---|---|
| Composition-of-matter patents | Historical Roche/Genentech coverage |
| Formulation patents | No marketed formulation estate with commercial relevance identified |
| Method-of-use patents | Clinical-use claims were pursued in the development program |
| FDA exclusivity | None because there was no approval |
| Orange Book-listed patents | None |
| Patent litigation affecting launch | No publicly identified generic litigation |
| Paragraph IV challenges | No commercially material Paragraph IV challenge identified |
No patent can create a viable product market after clinical discontinuation unless another sponsor establishes a new development path. For taselisib, the main barrier is no longer generic entry. It is the absence of an approved product and a failed late-stage benefit-risk profile.
When does taselisib lose exclusivity?
Taselisib has no operative FDA exclusivity period because it was never approved.
Patent expiry is more complicated than a single date because the program involved multiple patent families, continuations and potential patent-term adjustments. The earliest relevant U.S. composition-of-matter protection appears to reach the mid-2020s based on the earliest priority dates and published patent records.[4] Foreign expiry dates vary by jurisdiction.
A practical exclusivity timeline is:
| Period | Event |
|---|---|
| 2000s | Roche/Genentech PI3K-inhibitor patent families filed |
| 2011 onward | Taselisib enters clinical development |
| 2016-2018 | Late-stage development in breast cancer |
| 2018 | SANDPIPER reports; Roche does not pursue approval |
| 2019 | FDA approves alpelisib for a competing PIK3CA-mutated breast-cancer indication |
| Mid-2020s | Core patent terms for early families approach expiry, subject to adjustments |
| Current | No commercial product, no Orange Book protection, no generic launch pathway |
What formulations and methods of use were protected?
Taselisib development relied primarily on oral pharmaceutical administration. The relevant patent strategy likely included:
- Small-molecule PI3K-inhibitor composition claims.
- Pharmaceutical compositions containing taselisib or related compounds.
- Treatment of PIK3CA-mutated cancers.
- Combination treatment with endocrine therapy, including fulvestrant.
- Potential combination use with other anticancer agents.
The most valuable claimed use was treatment of PIK3CA-mutated HR-positive, HER2-negative breast cancer. That use was also the setting in which the clinical program failed to establish a commercially acceptable profile.
No approved extended-release, injectable, depot or device-based taselisib formulation created a separate market or patent barrier.
Which companies challenged or competed with taselisib?
No generic company became a material commercial challenger because taselisib never reached approval. The relevant competition came from branded PI3K and AKT pathway inhibitors.
| Drug | Company | Target | FDA status | Competitive position |
|---|---|---|---|---|
| Taselisib | Roche/Genentech | PI3K pathway, with PI3K alpha preference and broader isoform activity | Discontinued, not approved | No current market |
| Piqray, alpelisib | Novartis | PI3K alpha | Approved in 2019 | Direct benchmark in PIK3CA-mutated breast cancer |
| Truqap, capivasertib | AstraZeneca | AKT | Approved in 2023 | Competes in HR-positive advanced breast cancer |
| Itovebi, inavolisib | Roche/Genentech | PI3K alpha pathway | FDA approved in 2024 | Roche’s later, more targeted successor strategy |
| Idelalisib | Gilead | PI3K delta | Approved for hematologic cancers | Different disease and safety context |
Roche’s later development of inavolisib reflects a more selective approach to PI3K alpha biology and a different patient-selection strategy. Inavolisib was approved with palbociclib and fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer after recurrence on or after adjuvant endocrine therapy.[5]
How does taselisib compare with alpelisib and inavolisib?
Taselisib has no current commercial advantage against either drug because it lacks approval and failed its pivotal development program.
| Factor | Taselisib | Alpelisib | Inavolisib |
|---|---|---|---|
| Regulatory status | Discontinued | FDA approved | FDA approved |
| Primary pathway | PI3K pathway with broader isoform profile | PI3K alpha | PI3K alpha pathway |
| Key biomarker | PIK3CA mutation | PIK3CA mutation | PIK3CA mutation |
| Pivotal setting | HR-positive, HER2-negative breast cancer | HR-positive, HER2-negative breast cancer | HR-positive, HER2-negative breast cancer |
| Commercial availability | None | Commercially available | Commercially available |
| Main development issue | Toxicity and weak benefit-risk profile | Toxicity management remains important | Newer targeted positioning |
| Generic risk | None currently relevant | Patent and regulatory protection apply | Patent and regulatory protection apply |
Taselisib’s broader pathway activity may have contributed to its toxicity profile. The later market favored agents with more selective biology, clearer biomarker positioning and stronger pivotal-trial differentiation.
What is the market projection for taselisib?
Taselisib’s standalone market projection is effectively zero.
A base-case commercial forecast is:
| Scenario | Probability assessment | Revenue outlook |
|---|---|---|
| Roche launches taselisib in original breast-cancer indication | Not commercially credible | $0 |
| Taselisib is revived in a new indication | Low and unsupported by current development status | No reliable forecast |
| Taselisib is licensed to another company | No disclosed transaction or active program | $0 |
| Generic taselisib launch | Not applicable without FDA approval and product commercialization | $0 |
| Roche monetizes historical IP only | Possible in principle but no disclosed transaction | Immaterial to drug revenue |
The addressable market that taselisib once targeted is substantial, but that does not translate into taselisib revenue. The relevant market is now served by approved or advancing PI3K-pathway therapies, including alpelisib, inavolisib and capivasertib.
Roche’s 2024 approval of inavolisib provides the company with an active commercial position in the same broad biomarker-defined breast-cancer segment. That product should not be treated as a continuation of taselisib revenue. The compounds have separate clinical programs, labels, patent estates and benefit-risk profiles.[5]
Is there biosimilar or generic risk for taselisib?
There is no current biosimilar risk because taselisib is a small molecule, not a biologic.
Generic risk is also not commercially meaningful. A generic applicant would need an FDA-approved reference product to pursue the conventional abbreviated pathway. Taselisib has no approved reference listed drug, no Orange Book entry and no established market demand.
If a future sponsor obtained approval through a new NDA, patent and exclusivity analysis would restart around that approved product and its specific indication. Historical taselisib patents would not by themselves create a viable commercial franchise.
What licensing deals involve taselisib?
No major public licensing deal involving taselisib has been disclosed.
Roche and Genentech controlled the principal development program. The drug was not publicly transferred to a specialty pharmaceutical company after the SANDPIPER failure. No announced out-license, co-development agreement or asset sale has created a new commercial sponsor.
The absence of a transaction is consistent with the program’s limited residual value: the clinical risk was established, the original indication had competing approved therapies, and the patent estate was approaching the end of its most commercially useful period.
What patent litigation affects taselisib?
No publicly identified patent litigation has materially affected taselisib.
The relevant legal position is:
- No Orange Book patent dispute exists because taselisib has no approved product.
- No material Paragraph IV challenge has generated a launch event.
- No ANDA litigation has created a generic-entry timetable.
- No settlement agreement has established an authorized generic or delayed entry.
- No biosimilar litigation is applicable.
The absence of litigation does not indicate a strong active patent estate. It primarily reflects the absence of an approved, revenue-generating reference product.
How strong is the taselisib patent estate?
The historical composition-of-matter estate was more important than formulation or lifecycle patents. Its current strength is weak from a commercial perspective.
| Patent-estate factor | Assessment |
|---|---|
| Core chemical protection | Historically meaningful |
| Remaining term | Limited relative to a new launch |
| Regulatory exclusivity | None |
| Formulation differentiation | No commercially validated product |
| Method-of-use value | Reduced by clinical discontinuation |
| Freedom-to-operate relevance | Mainly historical |
| Litigation leverage | Low without an approved product |
| Licensing value | Limited unless a new clinical rationale emerges |
The key distinction is between patent validity and asset value. A surviving patent claim can remain legally enforceable while having little commercial value if the drug has no approval, no active clinical program and no credible path to market.
Key Takeaways
- Taselisib is a discontinued Roche/Genentech PI3K inhibitor.
- The Phase 3 SANDPIPER trial produced a modest PFS benefit of 7.4 versus 5.4 months.
- High rates of severe toxicity and treatment discontinuation prevented a favorable benefit-risk assessment.
- Taselisib was never approved by the FDA and has no Orange Book listing.
- No meaningful Paragraph IV, generic, biosimilar or patent-litigation threat exists.
- Historical Roche/Genentech patents covered PI3K-inhibitor compounds and related uses, with core terms reaching the mid-2020s subject to patent-specific adjustments.
- No major licensing deal or post-discontinuation asset transaction has been disclosed.
- Standalone taselisib revenue should be forecast at zero.
- Roche’s later inavolisib program, not taselisib, is the company’s active commercial strategy in PIK3CA-mutated breast cancer.
FAQs
Could taselisib return to clinical development?
A return is possible only through a new sponsor, new indication or substantially narrower biomarker strategy. No active public development program currently supports a relaunch forecast.
Is taselisib the same drug as inavolisib?
No. Both are associated with Roche and PI3K-pathway inhibition, but they are different chemical entities with separate clinical programs, labels and patent estates.
Can a generic company launch taselisib after its patents expire?
Not through the standard ANDA pathway without an FDA-approved reference product. Patent expiry alone does not create a generic market for an unapproved drug.
Did taselisib fail because the PIK3CA biomarker was invalid?
No. The biomarker remained clinically relevant, as shown by later approvals of alpelisib and inavolisib. Taselisib’s problem was the combination of limited efficacy improvement and high toxicity.
Does taselisib have any value in licensing or acquisition?
Its value is limited. A transaction would require a credible new clinical hypothesis, usable intellectual property and a development plan capable of competing with approved PI3K and AKT pathway therapies.
References
-
Baselga, J., Dent, S. F., Cortés, J., et al. (2018). Phase III study of taselisib plus fulvestrant in patients with PIK3CA-mutated breast cancer. The Lancet Oncology, 19(10), 1340-1351.
-
Roche. (2018). Roche provides update on Phase III SANDPIPER study of taselisib in advanced breast cancer. Roche press release.
-
U.S. Food and Drug Administration. (2019). FDA approves alpelisib for metastatic breast cancer with a PIK3CA mutation. FDA.
-
U.S. Patent No. 8,598,219. (2013). PI3K inhibitor compounds. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). FDA approves inavolisib with palbociclib and fulvestrant for PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. FDA.
More… ↓
